Task force at mash unit for Special Surgery have lucid two new targets for drugs aimed at superintending lupus. If companies are able to develop drugs that hone in on these targets, patients may be able to control their disease with few side effects."The study identifies very good therapeutic targets, and what needs to be done is identify better candidate drugs," said Lionel Ivashkiv, M.D. [click link for full article]

More: - Continued here